North America Arrhythmia Management System Market Size, Growth, Share, Trends & Forecast 2030

According to the Reports and Insights analysis, North America arrhythmia management system market is estimated for US$ 3,454.5 Mn in 2022 and is projected to register a CAGR of 6.6% to reach US$ 5,778.6 Mn by 2030 end. In 2021, the United States region is account for the prominent market share in comparison to Canada.

Soaring technological advancements in cardiac monitoring devices and systems is expected to boost the market

Atrial fibrillation (AF) is a common and prevalent form of arrhythmia. It is associated with numerous diseases with stroke being the serious threat. Since atrial fibrillation is by and large said to be asymptomatic, majority of the individuals continue to be oblivious of their condition and may not obtain the necessary treatment in due time. Therefore, the inspection and timely diagnosis of atrial fibrillation has gained good deal of attention in recent times. The soaring advancements in technology has led its way for several approaches for atrial fibrillation inspection using clinically-prescribed devices as well as consumer electronic devices. The newer ECG devices the healthcare industry possess now are immensely less heavy and clumsy. It is like wearing a Band-Aid in comparison to carrying a chunky device.

Moreover, patients these days, choose the more comfortable, wire-free form factor, and superior quality medical treatment and devices. For instance, Mawi, inventors of AI-powered wearable medical devices for cardiac disease monitoring and diagnosis, recently announced the official launch of Mawi Heart Patch, the first of its kind, disposable two-lead cardiac monitor. Mawi Heart Patch can be classified as a stick-and-go, wireless solution that aids in improving the recognition of cardiovascular diseases, by 3 times the speed of other techniques. It provides an elaborated report within 24 hours after monitoring is done, the solution lessens time to diagnosis by 97% and makes sure patients get access to life-saving treatment in due time.

Furthermore, there are next-gen state-of-the-art wearable devices like the Cardea SOLO ECG System that make this screening and monitoring process much handier and more comfortable for the rural patient and the physician likewise. These devices can accumulate data for an extended period of time unlike a Holter monitor — generally around a week’s worth. Such extensive information reduces the back-to-back commutes to the doctor’s office, which is specifically difficult for patients who live far away or in rural areas. Attributing to such technological advances and innovations, the global arrhythmia management system market is estimated to rise substantially over the years.

Rise in prevalence of cardiovascular diseases across the region is expected to propel the demand of arrhythmia management system market

Cardiovascular disease (CVD) can be understood as a generic name for clinical conditions distressing the blood vessels or the heart. Heart and blood vessels associated disease comprises several issues, majority of which are associated with a process known as atherosclerosis. Atherosclerosis can be classified as a medical condition that emerges when a substance commonly called as plaque accumulates in the walls of the arteries. This pileup contracts the arteries, making it difficult for blood to flow across. If a blood clot built, it may obstruct the blood circulation. This may result in a heart stroke or attack. In the United States, around 610,000 people succumb to heart disease each year. That is 1 of every 4 fatalities. It has been recorded that 75% of acute myocardial infarctions take place from plaque breakage and the highest incidence of plaque breakage was reported in men over 45 years; whilst, in women, the incidence rises over the age of 50 years. Atrial fibrillation (AF) is also one of the most prevalent and common sorts of arrhythmia.

Also, commonly termed as AF or AFib, it can be understood as an erratic heart rhythm (arrhythmia) that can pave its way to diverse heart-associated complexities such as stroke, blood clots, and heart failure. As per the estimations by the Centers for Disease Control and Prevention (CDC), the prevalence of AFib in the United States scales from around 2.7 million to 6.1 million. This figure is projected to surge to 12.1 million by 2030.

Moreover, coronary heart disease is witnessed as one of the leading causes of death in the Western countries claiming the lives of over 370,000 people every year. Angina pectoris can also be classified as an outcome of myocardial ischemia as a consequence of asymmetry between myocardial blood flow and oxygen demand. It is a commonly observed symptom (generally, chest pain) among patients with coronary artery disease (CAD). Around 9.8 million Americans are accounted to experience angina every year, with 500,000 new cases of angina taking place each year. Such high prevalence of cardiovascular diseases across the region is mainly driving the growth of the arrhythmia management system market.

Who are the Key players in Arrhythmia Management System Market?

Some of the key participating players in North America arrhythmia management system market are Asahi Kasei Corporation, Koninklijke Philips N.V., ACS Diagnostics, BioTelemetry, Inc., Medicomp Inc., CardioView, Medtronic plc, Preventice Solutions, Inc., ScottCare Cardiovascular Solutions, Hill-Rom Holdings, Inc., and Schiller Americas, Inc.

Recent Key Developments by Key Players of arrhythmia management system market are as follows:

• In March 2022, ZOLL Medical Corporation launched of the ZOLL Arrhythmia Management System (AMS). ZOLL AMS adds biometric data (heart rate, activity, respiratory rate, and body posture) to the ECG information provided by traditional MCT devices. A new study demonstrates that ZOLL AMS helps physicians make more informed patient treatment plans.

• In January 2021, Boston Scientific entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors – including short and long-term Holter monitors – to cardiac event monitors and mobile cardiac telemetry.
• In May 2018, Preventice Solutions announced today the launch of the BodyGuardian MINI, the smallest, reusable long-term Holter technology available for cardiac monitoring.

What are the Key Segments Covered in Arrhythmia Management System Market Report?

The North America arrhythmia management system market is segmented by system type, modality, type, disease indication, end use industry and by region

By Technology

Holter Monitors

Event Monitors

Mobile Cardiac Telemetry (MCT) Devices

TELErhythmics Cardiac Ambulatory Telemetry (TCAT) Device

Insertable Cardiac Monitoring (ICM)

By Disease Indication

Cardiovascular

Angina Pectoris

Atherosclerosis

Heart Failure

Others

By Type

Single Channel

Multi-Channel

By Modality

Wired

Wireless

By End-Use

Hospitals

Cardiac Centers

Diagnostic Centers

Homecare Settings

Ambulatory Surgical Centres

Others

By Country

The U.S.

Canada